Reply to: "Diabetes and Neuroaxonal Damage in Parkinson's Disease"

Affiliations

¹ Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
² Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.

Comment

Carsten Buhmann et al. Mov Disord. 2022 Jul.

. 2022 Jul;37(7):1569-1570.

doi: 10.1002/mds.29064.

¹ Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
² Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.

No abstract available

Comment on

Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson's Disease (MARK-PD Study).
Uyar M, Lezius S, Buhmann C, Pötter-Nerger M, Schulz R, Meier S, Gerloff C, Kuhle J, Choe CU. Uyar M, et al. Mov Disord. 2022 Jun;37(6):1299-1304. doi: 10.1002/mds.29009. Epub 2022 Apr 6. Mov Disord. 2022. PMID: 35384057
Diabetes and Neuroaxonal Damage in Parkinson's Disease.
Vijiaratnam N, Lawton M, Real R, Heslegrave AJ, Guo T, Athauda D, Gandhi S, Girges C, Ben-Shlomo Y, Zetterberg H, Grosset DG, Morris HR, Foltynie T; PRoBaND Clinical Consortium. Vijiaratnam N, et al. Mov Disord. 2022 Jul;37(7):1568-1569. doi: 10.1002/mds.29067. Mov Disord. 2022. PMID: 35856732 Free PMC article. No abstract available.

1. Vijiaratnam N, Lawton M, Real R, et al. Diabetes and neuroaxonal damage in Parkinson's disease. Mov Disord 2022;37(7):1568-1569.
1. Uyar M, Lezius S, Buhmann C, et al. Diabetes, Glycated haemoglobin (HbA1C), and neuroaxonal damage in Parkinson's disease (MARK-PD study). Mov Disord 2022;37(6):1299-1304. https://doi.org/10.1002/mds.29009
1. Pötter-Nerger M, Dutke J, Lezius S, et al. Serum neurofilament light chain and postural instability/gait difficulty (PIGD) subtypes of Parkinson's disease in the MARK-PD study. J Neural Transm (Vienna) 2022;129(3):295-300.
1. Niemann L, Lezius S, Maceski A, et al. Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD). Parkinsonism Relat Disord 2021;90:44-48.